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“Disease mongering” is the practice of widening diagnostic boundaries of a disease and 
promoting their public awareness to expand the markets for treatment and to increase profits. This 
tactic typically used by pharmaceutical companies, medical equipment manufacturers, insurance 
companies, and even some doctors and patient groups, has become a great concern. Its start is 
associated with the 1879 invention of Listerine, when its inventors created an obscure medical 
condition called “halitosis” to advertise the first over-the-counter mouthwash. Disease mongering 
has since increased in parallel with “medicalization,” which attempts to label normal human 
conditions as medical problems, thus becoming the subject of medical study, diagnosis, 
prevention, or treatment. Although some pharmaceutical companies closely follow their industry’s 
codes of ethics, many take advantage of their customers. However, medical professionals hold a 
greater moral obligation to their patients to do no harm. This paper first seeks to examine how an 
increasing amount of life’s natural conditions and ailments are being seen as medical conditions. 
This issue may be attributed to the conceptual framework in which a disease is outlined and 
defined. I will then argue that this alone does not result in disease mongering, rather third parties’ 
attempt to make these conditions seem more serious and widespread than they actually are 
contributes to the problem. Furthermore, the treatments for these problems are oversold despite 
sometimes being ineffective or causing more problems on top of the ones they claim to treat. De-
medicalization based on respect for human dignity, rather than investor value, is long overdue. The 
unethical practice of disease mongering can only be combated with joint initiatives from patients, 
providers, and the general public.  
 The most foundational question that dominates philosophy of medicine in this generation 
is: what is disease? This fundamental question encompasses how categorizing disease can depend 
on the general nature of disease. What arises from asking these kinds of questions has very 
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practical consequences—how we assess what is or is not considered a genuine disease can impact 
whether or not health insurance companies cover certain conditions. We believe to know what 
disease is when we see it and are quick to label cancer or cholera as diseases. However, trying to 
articulate and precisely define disease is more elusive. This ambiguity leaves open the possibility 
of blurring the lines between conditions that are serious, undesirable, or just a part of life’s natural 
condition. The conceptual framework utilized to define disease plays an important role in 
medicalization, which in turn influences the act of disease mongering. Before outlining the 
different conceptual approaches one can take to define disease, let us consider 3 patient vignettes: 
Tracy is a 34-year-old doctor who was referred to the sleep disorders centers for insomnia, 
non-restorative sleep, and a feeling of malaise throughout the day. Tracy’s sleep problems 
began during late adolescence and started with difficulty falling asleep. She also developed 
frequent awakenings throughout the night. She reported that the she experiences a sensation 
of urgency to move her legs in order to alleviate discomfort. Tracy was diagnosed with 
Restless Legs Syndrome (RLS) and was advised to decrease her caffeine intake and 
complete a daily leg exercise regime. These measures did little to decrease Tracy’s RLS 
symptoms. Further investigation concluded that Tracy’s RLS was an underlying symptom 
of her iron deficiency caused by her frequent blood donations. Once she stopped the 
donation and started taking daily iron supplements her RLS symptoms stopped.1 
Natalia is 41 years old and complains of having low sexual desire since the birth of her 
children, who are now four and six. She describes her marriage as “fine.” The children are 
not causing problems, and her husband, Daniel, is a good father and a considerate person. 
Natalia is not clinically depressed, has no history of depression and takes no medication. 
Her general health is fine, with regular periods. She has a busy part-time job which she 
enjoys. Natalia denies any spontaneous sexual thinking, need to masturbate or having 
anything other than the very occasional sexual dream. None of this has changed throughout 
her adult life. Natalia does not get aroused and expresses no desire to put in the necessary 
focusing and effort required to reach orgasm. Her working diagnosis points to some kind 
of sexual dysfunction.2 
Celina is 29 years old and presents to the clinic in distress. During the examination she 
fidgets and has a hard time sitting still. She has a hard time with time management and 
tends to be disorganized. She chronically misplaces everyday objects like her keys and runs 
late to appointment. Although she wants her work to be perfect, she is prone to making 
careless mistakes. The struggle for perfection makes starting a new task feel very stressful, 
leading her to procrastinate starting in the first place. Consequently, she has recently 
 
1 “A Case Study in Restless Leg Syndrome (RLS).” National Sleep Foundation. 
2 Basson, Rosemary. "Women’s Sexual Response and." Canadian Journal 131 (2001). 
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received several warnings from her boss related to missing deadlines for assignments and 
errors in her work, which has led to her acute fear of being fired. As a child, she received 
extra time for test taking in school, but never had any formal neuropsychological testing. 
After some additional assessments, Celina was formally diagnosed with adult attention 
deficit hyperactivity disorder (ADHD).3 
 The immediate question raised by these case studies is the central dilemma of philosophy 
of medicine, what is disease? How this question is answered largely depends on what conceptual 
framework of disease one is willing to accept. A naturalist position argues that disease is a 
malfunctioning physiological system.4 Christopher Boorse’s biostatistical theory of disease, the 
most prominent naturalist account of disease, characterizes a disease as “a type of internal state 
which is either an impairment of normal functional ability, i.e. a reduction of one or more 
functional abilities below typical efficiency, or limitation on functional ability caused by 
environmental agents.”5 A naturalist theory of disease holds that if we can locate a 
pathophysiological basis of a condition, such as  Tracy’s RLS, Natalia’s female sexual dysfunction 
disorder, or Celina’s ADHD, then we can classify them as a disease. On the other hand, a 
normativist account holds that to call a condition a disease is to hold that a person with that 
condition is harmed by it.6 Normativism argues that the concept of disease is value-laden, and 
claims that the condition is not merely biologically unusual, rather that the condition is bad for 
people who have it. Essentially, diseases are disvalued states which rely on our own evaluation of 
those states to determine whether or not a condition is bad for a person. Finally, the hybridist 
account of disease which serves as a middle ground between naturalism and normativism  holds 
that a disease must involve abnormal physiological functioning and that abnormal physiological 
 
3 "Jen (attention-deficit/hyperactivity Disorder)." Society of Clinical Psychology. 
4 Stegenga, Jacob. “Disease.” In Care and Cure: An Introduction to Philosophy of Medicine, 22–22. The University 
of Chicago Press, 2018. 
5 Boorse, Christopher. "A rebuttal on health." In What is disease?, pp. 1-134. Humana Press, Totowa, NJ, 1997. 
6 Stegenga, Jacob. “Disease.” In Care and Cure: An Introduction to Philosophy of Medicine, 26. The University of 
Chicago Press, 2018. 
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functioning must be disvalued in order for that condition to be classified as a disease.7 With the 
conceptual framework outlined, according to naturalism we could only classify Tracy’s RLS as a 
disease, while both normativist and hybridist would classify all three patients as presenting a 
disease.  
Since western medicine overall adopts a naturalist approach towards health and disease, 
which might suggest that naturalism is the least flawed approach to medicine, I will use this 
conceptual framework to form the rest of my argument going forward. While one might argue that 
any of the existing conceptual frameworks used to outline and define disease could very well result 
in overdiagnosis and medicalization, western medicine’s current approach towards disease has 
encouraged an environment where disease mongering is more prominent in society than ever. It is 
important to recognize though that in research targeting overdiagnosis, medicalization is often 
presented in terms of its societal burden of unnecessary medical expansion. The problem with this 
is that there is a focus that lies solely on the influence of medicine on society, while neglecting the 
influence of society on medicine. Although overdiagnosis and medicalization go hand in hand, the 
distinction between the two need to be made.  
Overdiagnosis occurs when a person is accurately diagnosed with the pathophysiological 
basis of a disease, however that pathophysiology would never cause any symptoms within the 
patient’s lifetime.8 When patients are then treated for the disease it becomes a case of 
overtreatment. Screening programs can lead to both overdiagnosis and overtreatment which can 
be a successful tactic used to disease monger. On the other hand, medicalization, as defined earlier, 
 
7 Stegenga, Jacob. “Disease.” In Care and Cure: An Introduction to Philosophy of Medicine, 30. The University of 
Chicago Press, 2018. 
8 Stegenga, Jacob. “Diagnosis and Screening.” In Care and Cure: An Introduction to Philosophy of Medicine, 182. 
The University of Chicago Press, 2018. 
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is the attempt to label normal human conditions as medical problems. When discussing 
overdiagnosis and medicalization and its consequences, there is an underlying assumption that 
classifying medical conditions as a disease and diagnosing these diseases is purely objective, this 
is untrue. Disease and illness are not merely just biological facts, but social constructions as well. 
Whether or not disease can be defined as entirely value-free or as unavoidably value-laden can be 
argued. However, we can agree that values play a large role in the perception of disease. Social 
agents such as government agencies and pharmaceutical companies can impose their values on 
health institutions through lobbying and policy making or promoting the awareness of diseases 
and advertising their treatments. 
Take for example, the 1879 invention of Listerine briefly mentioned at the beginning of 
this paper. In 1879, Dr. Joseph Lawrence and Jordan W. Lambert first marketed Listerine as a 
surgical antiseptic. Before long, its use was quickly spread beyond its original use, to being sold 
as a floor cleaner and as a treatment for gonorrhea. By 1895, it was marketed to dentist for oral 
care, and in 1914 it became the first over-the-counter mouthwash in the United States.9 To further 
advertise and market Listerine, the Lambert Pharmacal Company in conjunction with advertiser 
Gordan Seagrove, made up a disease called “halitosis,” meaning unpleasant breath, to which their 
product would “cure.” Promoting Listerine as a cure to halitosis resulted in raising the company’s 
total revenue from $115,00 to more than eight million dollars in only seven years.  
Consider again the danger of overdiagnosis and medicalization in loosely defining disease, 
specifically in psychiatry. The Diagnostic and Statistical Manual (DSM), published by the 
American Psychiatric Association (APA) leaves some forms of mental illness susceptible to 
 
9 Dossey, Larry. "Listerine's long shadow: disease mongering and the selling of sickness." Explore (New York, 
NY) 2, no. 5 (2006): 379. 
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disease mongering due to its use of an almost narrative definition of what disease is. Disease 
mongering expands the boundaries of treatable diseases resulting from strong commercial interest. 
Consequently, self-diagnosis is also becoming more prevalent in medicine due to the marketing 
practice of direct to consumer advertising. Think about the mental disorders describes previously 
in the patient vignettes that are endorsed by the DSM—ADHD and Premenstrual Dysmorphic  
Disorder. ADHD is the second most common mental health diagnosis, with schoolteachers playing 
a critical role in the determining who is at “risk” of ADHD in the classroom. This becomes 
problematic considering that websites funded by pharmaceutical companies are targeting teachers 
and providing “education” on the diagnosis and management of ADHD.10 Similarly, December of 
2012 marked the approval of the DSM-5, which also approved PMDD to have its own diagnostic 
category, thus marking PMDD as a mental disorder.11 Classifying PMDD as a distinct disorder 
further encourages the marketing of new treatments for the disorder. 
Even with all this evidence, some may argue that disease mongering poses no threat to 
society or medical institutions. If people are being treated for diseases they seem to have, what is 
so wrong with that? The question that is often posed with any argument is, so what? In a very 
practical sense, disease mongering results in a battle between private enterprises like 
pharmaceutical companies and public health. The pharmaceutical industry is a business and 
operates as such. Their concerns are not geared towards the patients their drugs are supposed to 
treat, rather the profits that arise from using their drugs as a treatment option. The United States’ 
current Medicare policy prohibits negotiation with drugs companies to lower the prices of their 
 
10 Saddichha, Sahoo. “Disease mongering in psychiatry: fact or fiction?” JNMA; journal of the Nepal Medical 
Association 50 180 (2010): 320-7. 
11 Epperson, C. Neill, Meir Steiner, S. Ann Hartlage, Elias Eriksson, Peter J. Schmidt, Ian Jones, and Kimberly A. 
Yonkers. "Premenstrual dysphoric disorder: evidence for a new category for DSM-5." American Journal of 
Psychiatry 169, no. 5 (2012): 465-475. 
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drugs. This gives pharmaceutical companies free rein over the cost of medication. To put in 
perspective, in 2018 the total nominal spending on medicines in the U.S was approximately $482 
billion, an almost $200 billion increase from 2008.12 Our partially tax-funded healthcare system 
simply cannot sustain the increasing cost of drug treatment for all the conditions pharmaceutical 
companies seek to treat the population. Not only is it concerning that hundreds of billions of dollars 
are being spent on medication that the average American cannot afford, but some doctors are also 
in on the game. In 1997, pharmaceutical companies’ total spending on marketing to physicians 
was $15.6 billion, and by 2016, it increased to $20.3 billion.13 Marketing to physician may include 
sending paid representatives to doctors’ offices to talk about a drug, free samples of drugs, or even 
compensating physicians for speaking engagements about the drug.14 While the American Medical 
Association (AMA) has put strict limits to this, there is still a major conflict of interest that comes 
from physicians being compensated by pharmaceutical companies for advertising/marketing 
certain drugs, and if the numbers do not spark any red flags consider the five principles of medical 
ethics—beneficence, non-maleficence, justice, utility, and autonomy—which are closely related 
to the two aims of medicine—to care and to cure. 
The principle of beneficence is to promote the welfare of others. This is inherent in the 
patient-physician relationship. Healthcare providers must take positive steps towards helping their 
patients, which closely relates to the second principle of non-maleficence. The obligation of non-
maleficence is to do no harm. While the principle of beneficence is closely related to the principle 
of non-maleficence, obligations to do no harm are often stricter than an obligation to help. For 
instance, the obligation to treat an injured or dying person is arguably more important than helping 
 
12 "U.S. Total Medicine Spending 2002-2018." Statista.  
13 Foley, Katherine Ellen. "Big Pharma Spent an Additional $9.8 Billion on Marketing in the past 20 Years. It 
Worked." Quartz. January 08, 2019. 
14 Ibid 
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the needy even if it involves doing a minor harm to a person. The third principle of utility attempts 
to bring about the greatest amount of good to benefit as many people involved as possible. The 
principle of justice, also known as distributive justice, states that there should be an element of 
fairness in all medical decisions. This fairness extends to decisions that burden and benefit. 
Additionally, there should also be an equal distribution of scarce resources and new treatments. 
Finally, the fifth principle of medical ethics is autonomy. The principle of autonomy says that 
people are typically rational, self-determining beings who are capable of making judgements and 
decisions for themselves and should be able to make these decisions with liberty—free from 
controlling influence—and agency. Many of these principles are violated by the act of disease 
mongering. Rather than promote patient autonomy through informed choice and beneficence, the 
pharmaceutical industry engages in misleading drug advertising and manufacturing new but 
questionable disease categories like restless leg syndrome or attention deficit hyperactivity 
disorder. This results in an increase of drug consumption, consequently increasing the risk of harm 
emerging from inappropriate drug use, which violates the principle of non-maleficence. 
Additionally, by creating medically unnecessary demands for health-related goods or services, 
disease mongering worsens the problem of an increasing cost of healthcare, thus violating the 
principle of justice. It is clear now the issues that arise from disease mongering, the question left 
to answer is how do we address or combat this? 
A key element to addressing disease mongering is education, chiefly educating those who 
have the ability to confront the primary perpetrators. The influence of the pharmaceutical industry 
clearly permeates the medical field and consumer advertising. While medical professionals do not 
have authority over how pharmaceutical companies market and advertise their products, they do 
have some authority over how they care for their patients. Physicians should not have any financial 
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ties to pharmaceutical companies and if they do, these industry affiliations should be disclosed and 
made aware to their patients. Additionally, our paternalistic approach to medicine, where the 
“doctor knows best,” needs to be evaluated. It is common for the general public to blindly accept 
medical conditions and treatments because of this paternalistic approach. Patients should be 
encouraged to learn more about their conditions, rather than blindly accept their medical diagnosis. 
This does not mean that they should be distrustful or skeptical of their doctors, rather educate 
themselves on the information their physicians are relaying to them and get in the habit of 
intuitively asking questions. Physicians too, should investigate treatments and conditions that are 
being advertised and marketed to them by pharmaceutical companies. It is vital that the 
pharmaceutical industry’s role in the development of disease be addressed, and joint initiative from 
patients, providers, and the general public is crucial to combatting disease mongering. 
Disease mongering is largely a result of western medicine’s overdiagnosis and 
medicalization of life’s normal human conditions. Pharmaceutical companies utilize this 
phenomenon to manufacture and promote diseases in order to advertise and sell their drugs as 
treatments. While it is clear the influence medicine has on society, the influence society has on 
medicine needs more research since societal perceptions of disease play a role in both 
overdiagnosis and medicalization. With disease mongering violating almost all the five principles 
of medical ethics, practical steps need to be taken in order to combat it. Medical professionals 
should disentangle themselves from the hold pharmaceutical companies have on them. There is a 
reason pharmaceutical companies spend billions of dollars to educate and sponsor physicians. In 
turn both patients and physicians should educate themselves as well. If physicians want to continue 
to truly care for their patients, there needs to be a bigger emphasis on the respect for human dignity, 
rather than how much profit we can get out of them. 
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